Our products

Polpharma’s strategic investment in HPAPI facility, the first of this kind in Poland

In 2022, we are opening a new chapter in the […]

Safe approach in delivering nitrosamine-free API products

N-nitrosamine impurities have been in the news for some years […]

Polpharma partners with Pikralida biopharmaceutical start-up

Polpharma has established cooperation with Pikralida, a biopharmaceutical start-up that […]

September 2019 was the date when the transformation process started in the API Business Unit of Polpharma.

This process targets clear information flow from an efficiency perspective based on KPIs, facilitating rapid…

Searching for new, better, and innovative solutions. Digital Transformation at Polpharma API.

People and their ability to change are the key drivers of each transformation.

Polpharma API Business Unit (API BU) completed step 1. Risk Evaluation according to EMA’s request concerning presence of nitrosamines in drug products.

As of September 26, 2019, EMA’s Human Medicines Committee (CHMP) requested as a matter of…

Why particles size is important in pharmaceutical industry? Is it really problematic?

In the pharmaceutical industry, particle size has become one of the key aspects in the…

Polpharma’s strategic investment in HPAPI facility
We have launched an investment in a specialized facility
for the R&D and Production of highly active substances
with an OEL value of 10 ng/m3 (OEB 6).

The HP API investment includes separate process
laboratories (PDL), analytical laboratories (ADL)
with the possibility of performing Quality Control
analyses, and a GMP kilo-lab production line with
volume up to 1.5 kg with potential volume increase.